Trial Profile
Study of the pharmacokinetic variability of sunitinib in patients with metastatic kidney cancer : research pharmacogenetic determinants
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Pharmacokinetics
- Acronyms GenCInib-suni
- 28 Jan 2020 Status changed from recruiting to completed.
- 14 Jul 2016 New trial record